. 2023 Jan 3;6:2. doi: 10.1038/s42003-022-04398-2

Table 2.

Clinical and neuropathological information, age and sex of each individual included in the plasma amylin and brain amylin and Aβ analyses by ELISA, and in the IHC analysis of cerebrovascular amylin-Aβ co-localization.

#	Sex	Age	Type-2 DM	Braak stage	Amyloid Angiopathy	MMSE	CERAD
1	F	95	NO	0	NO	26	A=CERAD possible
2	F	97	NO	4	NO	24	A=CERAD possible
3	M	92	NO	0	NO	30	NO
4^a	F	90	NO	3	NO	29	NO
5	F	75	NO	1	NO	23	NO
6	F	84	NO	0	NO	30	NO
7	F	84	NO	1	NO	29	NO
8^a	F	85	NO	4	MILD	23	NO
9	F	93	NO	2	NO	30	NO
10	F	96	NO	2	MODERATE	30	NO
11^a	F	90	NO	2	MILD	30	NO
12^a	F	80	NO	1	NO	28	NO
13	M	87	YES	2	NO	27	NO
14^a	F	84	YES	1	MILD	26	NO
15	F	92	YES	2	NO	29	NO
16^a	F	87	YES	3	NO	28	NO
17^a	F	90	YES	2	NO	29	NO
18^a	F	69	YES	1	NO	29	NO
19	F	87	NO	4	MILD	30	C=Definite AD
20	F	78	NO	6	MILD	0	C=Definite AD
21^a	F	91	NO	2	MODERATE	29	B=CERAD probable
22	M	78	NO	6	MILD	15	C=Definite AD
23^a	M	85	NO	6	MODERATE	16	B=CERAD probable
24^a	F	93	NO	2	NO	29	B=CERAD probable
25^a	M	84	NO	4	MODERATE	24	B=CERAD probable
26	M	89	NO	1	MILD	26	C=Definite AD
27	M	73	NO	6	NO	16	C=Definite AD
28	F	88	NO	3	NO	28	C=Definite AD
29^a	M	75	NO	6	SEVERE	5	C=Definite AD
30	F	101	NO	4	NO	26	B=CERAD probable
31^a	M	98	NO	2	SEVERE	24	B=CERAD probable
32^a	F	92	NO	5	MILD	19	C=Definite AD
33	M	79	NO	6	MILD	6	C=Definite AD
34^a	F	91	NO	5	MILD	13	C=Definite AD
35	M	67	NO	6	MILD	11	C=Definite AD
36^a	F	87	NO	3	MILD	30	B=CERAD probable
37	F	98	NO	4	NO	13	B=CERAD probable
38	M	91	NO	1	SEVERE	28	NO
39	F	79	YES	6	SEVERE	19	C=Definite AD
40	F	86	YES	2	NO	30	B=CERAD probable
41	F	91	YES	3	MILD	25	B=CERAD probable
42	F	91	YES	5	MODERATE	9	C=Definite AD
43	M	87	YES	3	NO	21	A=CERAD possible
44	M	75	YES	5	MILD	28	C-Definite AD
45	F	86	YES	6	MILD	14	C-Definite AD
46^a	M	77	YES	4	MILD	30	B=CERAD probable
47^a	M	86	YES	2	NO	28	A=CERAD possible
48^a	M	81	YES	1	NO	26	A=CERAD possible
49	M	86	YES	6	MODRATE	29	C-Definite AD
50	F	93	YES	4	MODERATE	28	B=CERAD probable
51	M	96	YES	4	MILD	21	B=CERAD probable
52	M	89	YES	4	MODERATE	26	B=CERAD probable
53	M	85	YES	6	SEVERE	4	C-Definite AD
54	F	83	YES	4	MODERATE	23	B=CERAD probable
55	F	81	YES	5	MILD	14	C-Definite AD
56	F	85	YES	2	NO	24	B=CERAD probable
57	F	84	YES	6	SEVERE	7	C-Definite AD
58	F	81	YES	5	MODERATE	13	C-Definite AD
59	F	88	YES	6	MODERATE	29	C-Definite AD
60	M	85	YES	3	NO	30	A=CERAD possible
#	Sex	Age	Type-2 Diabetes	AD	Amyloid Angiopathy		Clinical finding
1^b	M	77	YES	No	NO		MCI
2^b	M	82	YES	No	Severe		MCI
3^b	M	83	YES	Yes	Severe		DEMENTED
4^b	F	77	YES	No	NO		DEMENTED
5^b	M	90	NO	Yes	Severe		DEMENTED
6^b	F	91	NO	No	Severe		NORMAL
7^b	M	93	NO	Yes	Severe		DEMENTED
8^b	F	77	YES	No	NO		NORMAL
9^b	M	88	NO	No	Severe		DEMENTED
10^b	M	91	NO	Yes	Severe		DEMENTED
11^b	M	84	NO	No	NO		NORMAL
12^b	M	95	NO	No	NO		MCI
13^b	F	81	YES	No	NO		NORMAL
14^b	F	90	NO	Yes	Severe		DEMENTED
15^b	F	87	YES	Yes	NO		DEMENTED
16^b	M	87	NO	Yes	Severe		DEMENTED
17^b	F	77	YES	Yes	Severe		DEMENTED
18^b	M	79	YES	yes	Severe		DEMENTED

The absence/presence of diabetes was determined during life (at longitudinal clinical visits) by patient or caregiver self-report and the use of diabetic medications. The assessment of clinical dementia and the neuropathologic features - neuritic amyloid plaques (Consortium to Establish a Registry for Alzheimer’s Disease; CERAD), Braak NFT stage and cerebral amyloid angiopathy (CAA) severity - were scored as previously described^27–31. ^aPlasma samples from these patients were used in amylin ELISA measurements. ^bThese brain samples were used in immunohistochemistry.